RESUMO
Las guías clínicas latinoamericanas de hipertensión arterial (HTA), elaboradas a la medida de las necesidades de los países de Centro y Sudamérica deben ser aplicadas y conocidas por la mayoría de los médicos latinoamericanos. El conocimiento e implementación de las guías es uno de los mayores desafíos de las sociedades de hipertensión del área latinoamericana tales como la Sociedad Centroamericana y del Caribe de Hipertensión Arterial (SCCH), la Sociedad latinoamericana de Hipertensión (LASH) y La Sociedad Interamericana de Cardiología (SIAC). En el año 2020, la SIAC publicó su posicionamiento sobre las guías vigentes de hipertensión arterial debido a la necesidad de estandarizar la evaluación, diagnóstico, tratamiento y control de la HTA, estableciendo recomendaciones que deberían adoptarse en todos los países de América Latina, encaminadas a optimizar el manejo del riesgo cardiovascular y conseguir una mejora sustancial en la disminución de eventos y mortalidad cardiovascular. El presente documento pretender reforzar las propuestas de la guía LASH y el posicionamiento de la SIAC en relación con el abordaje terapéutico y recomendaciones de tratamiento farmacológico de la HTA, con la finalidad de que se logre un mejor control de HTA en el área Centroamericana y del Caribe y, consecuentemente, mejorar el pronóstico de las enfermedades cardiovasculares en el área. (AU)
Latin American hypertension guidelines, tailored to the needs of countries of Central and South America, should be applied and known by most Latin American physicians. The knowledge and implementation of the Guidelines is one of the greatest challenges of hypertension societies in Latin America such as the Central American and Caribbean Society of Arterial Hypertension (SCCH), the Latin American Society of Hypertension (LASH) and the Inter-American Society of Cardiology (SIAC). In 2020, the Inter-American Society of Cardiology (SIAC) published its position on the current Guidelines for Arterial Hypertension due to the need to standardize the evaluation, diagnosis, treatment and control of hypertension, establishing recommendations that should be adopted in all Latin American countries, aimed at optimizing the management of cardiovascular risk and achieving a substantial improvement in the reduction of cardiovascular events and mortality. This document intends to reinforce all proposals by the LASH guidelines and the position of the SIAC in relation to the therapeutic approach and pharmacological recommendations for patients with hypertension (HT), in order to achieve better HT control in the Central American and Caribbean area, and the consequently prognosis improvement of cardiovascular disease in the area. (AU)
Assuntos
Humanos , Hipertensão/diagnóstico , Hipertensão/tratamento farmacológico , Hipertensão/prevenção & controle , América Central , Região do Caribe , Guias como AssuntoRESUMO
Latin American hypertension guidelines, tailored to the needs of countries of Central and South America, should be applied and known by most Latin American physicians. The knowledge and implementation of the Guidelines is one of the greatest challenges of hypertension societies in Latin America such as the Central American and Caribbean Society of Arterial Hypertension (SCCH), the Latin American Society of Hypertension (LASH) and the Inter-American Society of Cardiology (SIAC). In 2020, the Inter-American Society of Cardiology (SIAC) published its position on the current Guidelines for Arterial Hypertension due to the need to standardize the evaluation, diagnosis, treatment and control of hypertension, establishing recommendations that should be adopted in all Latin American countries, aimed at optimizing the management of cardiovascular risk and achieving a substantial improvement in the reduction of cardiovascular events and mortality. This document intends to reinforce all proposals by the LASH guidelines and the position of the SIAC in relation to the therapeutic approach and pharmacological recommendations for patients with hypertension (HT), in order to achieve better HT control in the Central American and Caribbean area, and the consequently prognosis improvement of cardiovascular disease in the area.
